The FOXO4-DRI peptide eliminated cells in the Ctrl and DM1 groups, which is coherent with our scRNAseq data showing that FOXO4 is not specifically upregulated in the senescent cell population (Supplementary Fig. 9) Navitoclax selectively eliminated cells in DM1 samples at a specific concentration (3 μm); however, A1155463 was the most effective to target cells specifically in the DM1 group and not affect the healthy cell viability (Fig. 5a). The gene discussed is FOXO4; the disease is myotonic dystrophy type 1.